Ranitidine Hydrochloride Injection

This product is an H2 receptor antagonist. It replaces the imidazole ring of cimetidine with a furan ring. It has a higher selectivity for H2 receptors and can significantly inhibit the basal and nocturnal gastric acid secretion of normal people and ulcer patients, as well as the gastric acid secretion caused by pentagastrin, histamine and meals. Its potency in inhibiting gastric acid secretion is 5 to 12 times that of cimetidine in terms of moles. Intravenous injection of this product can reduce gastric acid secretion by 90%; it has a certain inhibitory effect on the secretion of pepsinogen. It has a protective effect on experimental gastric mucosal damage and acute ulcers. It has no effect on the secretion of gastrin and sex hormones.

The main ingredient of this product is: Ranitidine hydrochloride. Its chemical name is: Nprime;-methyl-N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]-methyl]thio]ethyl]-2-nitro-1,1-ethylenediamine hydrochloride. Structural formula: (see Ranitidine hydrochloride capsules) Molecular formula: C13H22N4O3SHCl Molecular weight: 350.87

Acid suppressants. Mainly used for: 1. Peptic ulcer bleeding, diffuse gastric mucosal lesions bleeding, anastomotic ulcer bleeding, prevention of rebleeding after gastric surgery, etc. 2. Acute gastric mucosal damage complicated by stress state, and acute gastric mucosal damage caused by aspirin; also commonly used to prevent the occurrence of stress ulcer bleeding under stress state of severe diseases (such as cerebral hemorrhage, severe trauma, etc.); 3. Prevent gastric acid reflux combined with aspiration pneumonia after general anesthesia or major surgery and in weak and comatose patients.

Adults: 1 Upper gastrointestinal bleeding: 50 mg each time, diluted and slowly dripped intravenously (1-2 hours), or slowly injected intravenously (over 10 minutes), or injected intramuscularly 50 mg, the above methods can be administered twice a day or once every 6-8 hours; 2 Preoperative administration: 50-100 mg slowly injected intravenously 60-90 minutes before general anesthesia or major surgery, or 5% glucose injection 200 ml diluted and slowly dripped intravenously for 1-2 hours. Children: intravenous injection: 1-2 mg/kg each time, once every 8-12 hours; intravenous drip: 2-4 mg/kg each time, continuous drip for 24 hours.

1. Common symptoms include nausea, rash, constipation, diarrhea, fatigue, headache, dizziness, etc., which are generally mild and can be relieved during continued medication; 2. Some patients experience facial heat and stomach tingling after intravenous injection, which disappear on their own after more than 10 minutes; itching and redness may occur locally after intravenous injection, which may disappear after 1 hour; 3. Bradycardia may occur occasionally after intravenous injection; 4. Compared with cimetidine, the adverse effects of damaging renal function, gonadal function and central nervous system are milder; 5. A small number of patients experience leukopenia or thrombocytopenia after medication, and the symptoms may disappear on their own after discontinuation of medication; 6. This product can cause mild liver damage, reversible increase in ALT, and the symptoms disappear after discontinuation of medication, and liver function also returns to normal. It may be a drug allergic reaction and has nothing to do with the dosage of the drug; 7. Occasionally, there may be fever, male breast development, nephritis, etc.

It is contraindicated for those with a history of allergies.

1. This product can reduce hepatic blood flow. When used in combination with certain drugs that are metabolized by the liver and greatly affected by hepatic blood flow, such as warfarin, lidocaine, cyclosporine, diazepam, propranolol (Inderal), etc., it can increase the blood concentration of the above drugs, prolong their duration and intensity of action, and may increase the toxicity of certain drugs, which is worthy of attention; 2. When used in combination with anticoagulants or anti-epileptic drugs, it is safer than cimetidine; 3. When used in combination with warfarin, it can reduce or increase prothrombin time.

Keep away from light and store in a sealed container.

5ml:50mg (calculated as C13H22N4O3S)

Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd.

• Founded in:

  1999-11-12

• Address:

  No. 166, North side of Xinxing Road, west side of Zhenxing Road, Liangyuan District, Shangqiu City

• Tax NO.:

  91411400716735619N

• Registered Funds:

  83.29 million yuan

• Website:

  Log in to view

• Email:

  Log in to view